Drugs / Salicylate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03447925 | Jun 2017 → Mar 2019 | palmoplantar keratosis | Universidade do Vale do Sapucai | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01712295 | Nov 2011 → Dec 2013 | plantar wart | Grossman, Michael, D.P.M. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salicylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01712295 ↗ |
| Route | Topical | “subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks” NCT01712295 ↗ |